Peio Azcoaga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peio Azcoaga has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Maria M. Caffarel
Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, Spain
3 shared publications Asís Palazón
Cancer Immunology and Immunotherapy Laboratory, CIC bioGUNE-BRTA, Derio, Spain
2 shared publications- Ainhoa Romo-Valera
Group of Breast Cancer, Biogipuzkoa Health Research Institute, San Sebastian, Spain
1 shared publication - Alexandar Tzankov
Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland
1 shared publication - Amaia Cipitria
Group of Bioengineering in Regeneration and Cancer, Biogipuzkoa Health Research Institute, San Sebastian, Spain
1 shared publication - Ander Urruticoechea
Biogipuzkoa (previously known as Biodonostia) Health Research Institute, San Sebastián, Spain; Gipuzkoa Cancer Unit/OSI Donostialdea - Onkologikoa, San Sebastián, Spain
1 shared publication
Latest Publications
- Open Access
- 24 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103128
Injectable and viscoelastic click alginate hydrogels for spatio-temporal T cell administration in vivo
- 24 April 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38, 103128
Open AccessInjectable and viscoelastic click alginate hydrogels for spatio-temporal T cell administration in vivo
- Top Cited PapersOpen Access
- 9 November 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007530
New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment. The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed.
- 9 November 2023
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (11) , e007530
Top Cited PapersOpen AccessNew perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment. The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed.
- Open Access
- 1 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (7)
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.
- 1 April 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (7)
Open AccessStromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.